|
[1]SATAPATHY SK, SABTAL AJ.Epidemiology and natural history of nonalcoholic fatty liver disease[J].Semin Liver Dis, 2015, 35 (3) :221-235.
|
|
[2]European Association for the Study of the Liver (EASL) , European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].Obes Facts, 2016, 9 (2) :65-90.
|
|
[3]CHIANG JY.Bile acid metabolism and signaling[J].Compr Physiol, 2013, 3 (3) :1191-1212.
|
|
[4]LI Y, JADHAV K, ZHANG Y.Bile acid receptors in non-alcoholic fatty liver disease[J].Biochem Pharmacol, 2013, 86 (11) :1517-1524.
|
|
[5]YUAN L, BAMBHA K.Bile acid receptors and nonalcoholic fatty liver disease[J].World J Hepatol, 2015, 7 (28) :2811-2818.
|
|
[6]DAWSON PA, KARPEN SJ.Intestinal transport and metabolism of bile acids[J].J Lipid Res, 2015, 56 (6) :1085-1099.
|
|
[7]RIDLON JM, BAJAJ JS.The human gut sterol biome:bile acid microbiome endocrine aspects and therapeutics[J].Acta Pharm Sin B, 2015, 5 (2) :99-105.
|
|
[8]VERNON G, BARANOVA A, YOUNOSSI ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther, 2011, 34 (3) :274-285.
|
|
[9]FAN JG, ZHU J, LI XJ, et al.Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai[J].Chin J Hepatol, 2005, 13 (2) :83-88. (in Chinese) 范建高, 朱军, 李新建, 等.上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志, 2005, 13 (2) :83-88.
|
|
[10]GERBER L, OTGONSUREN M, MISHRA A, et al.Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity:a population-based study[J].Aliment Pharmacol Ther, 2012, 36 (8) :772-781.
|
|
[11]LIU YL, PATMAN GL, LEATHART JB, et al.Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma[J].J Hepatol, 2014, 61 (1) :75-81.
|
|
[12]ANSTEE QM, DAY CP.The genetics of nonalcoholic fatty liver disease:spotlight on PNPLA3 and TM6SF2[J].Semin Liver Dis, 2015, 35 (3) :270-290.
|
|
[13]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.
|
|
[14]PIZARRO M, BALASUBRAMANIYAN N, SOLIS N, et al.Bile secretory function in the obese Zucker rat:evidence of cholestasis and altered canalicular transport function[J].Gut, 2004, 53 (12) :1837-1843.
|
|
[15]BOYER JL.Bile formation and secretion[J].Compr Physiol, 2013, 3 (3) :1035-1078.
|
|
[16]COPPLE BL, LI T.Pharmacology of bile acid receptors:Evolution of bile acids from simple detergents to complex signaling molecules[J].Pharmacol Res, 2016, 104 (1) :9-21.
|
|
[17]KONG B, WANG L, CHIANG JY, et al.Mechanism of TissueSpecific Farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice[J].Hepatology, 2012, 56 (3) :1034-1043.
|
|
[18]ZHANG Y, LEE FY, BARRERA G, et al.Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice[J].Proc Natl Acad Sci U S A, 2006, 103 (4) :1006-1011.
|
|
[19] STAYROOK KR, BRAMLETT KS, SAVKUR RS, et al.Regulation of carbohydrate metabolism by the farnesoid X receptor[J].Endocrinology, 2005, 146 (3) :984-991.
|
|
[20]SINAL CJ, TOHKIN M, MIYATA M, et al.Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J].Cell, 2000, 102 (6) :731-744.
|
|
[21]WATANABE M, HOUTEN SM, WANG L, et al.Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c[J].J Clin Invest, 2004, 113 (10) :1408-1418.
|
|
[22]FUCHS CD, TRAUSSNIGG SA, TRAUNER M.Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease[J].Semin Liver Dis, 2016, 36 (1) :69-86.
|
|
[23]MAZUY C, HELLEBOID A, STAELS B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci, 2015, 72 (9) :1631-1650.
|
|
[24]CHAO F, GONG W, ZHENG Y, et al.Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte[J].Atherosclerosis, 2010, 213 (2) :443-448.
|
|
[25]CARIOU B, CHETIVEAUX M, ZAIR Y, et al.Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults[J].Nutr Metab, 2011, 8 (1) :48.
|
|
[26]STAYROOK KR, BRAMLETT KS, SAVKUR RS, et al.Regulation of carbohydrate metabolism by the farnesoid X receptor[J].Endocrinology, 2005, 146 (3) :984-991.
|
|
[27]PRAWITT J, ABDELKARIM M, STROEVE JH, et al.Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J].Diabetes, 2011, 60 (7) :1861-1871.
|
|
[28]ZHAN L, LIU HX, FANG Y, et al.Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes[J].PLo S One, 2014, 9 (9) :e105930.
|
|
[29]DUBOC H, TACHE Y, HOFMANN AF.The bile acid TGR5 membrane receptor:from basic research to clinical application[J].Dig Liver Dis, 2014, 46 (4) :302-312.
|
|
[30]BROEDERS EP, NASCIMENTO EB, HAVEKES B, et al.The bile acid chenodeoxycholic acid increases human brown adipose tissue activity[J].Cell Metab, 2015, 22 (3) :418-426.
|
|
[31]THOMAS C, GIOIELLO A, NORIEGA L, et al.TGR5-mediated bile acid sensing controls glucose homeostasis[J].Cell Metab, 2009, 10 (3) :167-177.
|
|
[32]KUMAR DP, ASGHARPOUR A, MIRSHAHI F, et al.Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis[J].J Biol Chem, 2016, 291 (13) :6626-6640.
|
|
[33]PERINO A, SCHOONJANS K.TGR5 and immunometabolism:insights from physiology and pharmacology[J].Trends Pharmacol Sci, 2015, 36 (12) :847-857.
|
|
[34]GEIER A, DIETRICH CG, GROTE T, et al.Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat[J].J Hepatol, 2005, 43 (6) :1021-1030.
|
|
[35]MACALUSO FS, MAIDA M, PETTA S.Genetic background in nonalcoholic fatty liver disease:a comprehensive review[J].World J Gastroenterol, 2015, 21 (39) :11088-11111.
|
|
[36]IWATA R, BAUR K, STIEGER B, et al.A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in nonalcoholic fatty liver disease[J].Clin Sci, 2011, 120 (7) :287-296.
|
|
[37]JIANG C, XIE C, LV Y, et al.Intestine selective farnesoid X receptor inhibition improves obesity related metabolic dysfunction[J].Nat Commun, 2015, 6:10166.
|
|
[38]SAYIN SI, WAHLSTROM A, FELIN J, et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist[J].Cell Metab, 2013, 17 (2) :225-235.
|
|
[39]VAN BEST N, JANSEN PL, RENSEN SS.The gut microbiota of nonalcoholic fatty liver disease:current methods and their interpretation[J].Hepatol Int, 2015, 9 (3) :406-415.
|
|
[40]VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLABERTOT L, et al.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J].Gastroenterology, 2015, 149 (2) :367-378.
|
|
[41]AITHAL GP, THOMAS JA, KAYE PV, et al.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J].Gastroenterology, 2008, 135 (4) :1176-1184.
|
|
[42]LAVINE JE, SCHWIMMER JB, VAN NATTA ML, et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial[J].JAMA, 2011, 305 (16) :1659-1668.
|
|
[43]DONGIOVANNI P, PETTA S, MANNISTO V, et al.Statin use and nonalcoholic steatohepatitis in at risk individuals[J].J Hepatol, 2015, 63 (3) :705-712.
|
|
[44]ALI AH, CAREY EJ, LINDOR KD.Recent advances in the development of farnesoid X receptor agonists[J].Ann Transl Med, 2015, 3 (1) :5.
|
|
[45]MUDALIAR S, HENRY RR, SANYAL AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease[J].Gastroenterology, 2013, 145 (3) :574-582.
|
|
[46]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :a multicentre, randomised, placebocontrolled trial[J].Lancet, 2015, 385 (9972) :956-965.
|
|
[47]CORREIA JC, MASSART J, de BOER JF, et al.Bioenergetic cues shift FXR splicing towards FXRalpha2 to modulate hepatic lipolysis and fatty acid metabolism[J].Mol Metab, 2015, 4 (12) :891-902.
|
|
[48]PELLICCIARI R, GIOIELLO A, MACCHIARULO A, et al.Discovery of6alpha-ethyl-23 (S) -methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity[J].J Med Chem, 2009, 52 (24) :7958-7961.
|
|
[49]MCMAHAN RH, WANG XX, CHENG LL, et al.Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J].J Biol Chem, 2013, 288 (17) :11761-11770.
|
|
[50]HODGE RJ, NUNEZ DJ.The therapeutic potential of TGR5 agonists.Hope or hype?[J].Diabetes Obes Metab, 2016, 18 (5) :439-443.
|
|
[51]BERAZA N, OFNER-ZIEGENFUSS L, EHEDEGO H, et al.Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis[J].Gut, 2011, 60 (3) :387-396.
|
|
[52]RAO A, KOSTERS A, MELLS J, et al.Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice[J].Sci Transl Med, 2016, 8 (357) :357ra122.
|
|
[53]BAARS A, OOSTING A, KNOL J, et al.The gut microbiota as a therapeutic target in IBD and metabolic disease:a role for the bile acid receptors FXR and TGR5[J].Microorganisms, 2015, 3 (4) :641-666.
|
DownLoad: